SAN FRANCISCO - With the discovery of suitable molecular targets - cellular molecules along pathways crucial for sustaining the life of cancer cells - comes the perplexing dilemma of where to find the next therapeutics that will bind to and disable those targets. While the possibilities for drug designs are near-limitless, the methods to screen drug databases and repositories are often problematic or ill-suited for the particular needs of researchers.
